{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T11:15:24Z","timestamp":1792494924148,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T00:00:00Z","timestamp":1749427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T00:00:00Z","timestamp":1749427200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>This study aimed to assess the paediatric growth hormone deficiency burden in Greek patients and their caregivers regarding the health-related quality of life (HRQoL), impact of recombinant human growth hormone (rhGH) treatment, and disease management.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Method<\/jats:title>\n            <jats:p>In this cross-sectional study, Quality of Life in Short Stature Youth (QoLISSY) and Life Interference for GHD (LIQ-GHD) questionnaires were administered to both patients with pGHD aged 4\u201317 years receiving rhGH for minimum 12 months and their caregivers.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>This study included 250 patients and their caregivers. The mean (\u2009\u00b1\u2009SD) total QoLISSY scores were 80.93 (\u00b114.63) and 76.32 (\u00b117.68) reported by patients and caregivers, respectively. Patients\u2009\u2265\u20098 years scored higher in total and emotional domains compared to caregivers, whereas the treatment domain was lower in patients\u2009&gt;\u200912 years versus caregivers. Ease of injection schedule, life interference, and willingness to continue LIQ-GHD domains mainly comprised treatment burden, with mean (\u00b1SD) scores of 19.88 (\u00b122.02), 19.36 (\u00b118.39) and 19.25 (\u00b119.60), respectively. Treatment adherence in the overall population was satisfactory. Patients\u2009\u2265\u20098 years missed more injections than younger individuals.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>A good HRQoL and a mild treatment burden were reported by Greek patients receiving daily rhGH and their caregivers; however, variability was observed within children\u2019s and caregivers\u2019 groups. Considering the decreased compliance during adolescence, emphasis should be given to consultations with patients and caregivers to identify issues and address them accordingly. Finally, there is a need to consider alternative treatment regimens which could improve adherence.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s12020-025-04269-w","type":"journal-article","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T15:20:27Z","timestamp":1749482427000},"page":"858-868","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Quality of life and treatment burden of children receiving daily growth hormone treatment in Greece"],"prefix":"10.1007","volume":"89","author":[{"given":"Athanasios","family":"Christoforidis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fotini-Eleni","family":"Karachaliou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Assimina","family":"Galli-Tsinopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dionisios","family":"Chrysis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Kanaka-Gantenbein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelia","family":"Baxevanidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Skiadas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oresteia","family":"Zisimopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apostolia","family":"Poimenidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Tsilakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elpis-Athina","family":"Vlachopapadopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the GHEA Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia","family":"Sotiriou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Tsintzou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki-Rengina","family":"Tsinopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Efthymiadou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Nikolaou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Lekka-Emiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,9]]},"reference":[{"issue":"1","key":"4269_CR1","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2147\/CPAA.S6525","volume":"2","author":"CS Reh","year":"2010","unstructured":"C.S. Reh, M.E. Geffner, Somatotropin in the treatment of growth hormone deficiency and turner syndrome in pediatric patients: a review. Clin. Pharmacol. 2(1), 111\u2013122 (2010). https:\/\/doi.org\/10.2147\/CPAA.S6525","journal-title":"Clin. Pharmacol."},{"issue":"3","key":"4269_CR2","doi-asserted-by":"publisher","first-page":"206","DOI":"10.23736\/S0026-4946.20.05821-1","volume":"72","author":"JG Halas","year":"2020","unstructured":"J.G. Halas, A. Grimberg, Dilemmas of growth hormone treatment for GH deficiency and idiopathic short stature: defining, distinguishing, and deciding. Minerva Pediatr. 72(3), 206\u2013225 (2020). https:\/\/doi.org\/10.23736\/S0026-4946.20.05821-1","journal-title":"Minerva Pediatr."},{"key":"4269_CR3","doi-asserted-by":"publisher","first-page":"720419","DOI":"10.3389\/fendo.2021.720419","volume":"12","author":"MB Ranke","year":"2021","unstructured":"M.B. Ranke, Short and long-term effects of growth hormone in children and adolescents with GH deficiency. Front. Endocrinol. 12, 720419 (2021). https:\/\/doi.org\/10.3389\/fendo.2021.720419","journal-title":"Front. Endocrinol."},{"issue":"6","key":"4269_CR4","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1159\/000452150","volume":"86","author":"A Grimberg","year":"2017","unstructured":"A. Grimberg, S.A. DiVall, C. Polychronakos, D.B. Allen, L.E. Cohen, J.B. Quintos, W.C. Rossi, C. Feudtner, M.H. Murad, Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency. Horm. Res. Paediatr. 86(6), 361\u2013397 (2017). https:\/\/doi.org\/10.1159\/000452150","journal-title":"Horm. Res. Paediatr."},{"issue":"1","key":"4269_CR5","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1297\/cpe.18.15","volume":"18","author":"T Tanaka","year":"2009","unstructured":"T. Tanaka, S. Tai, Y. Morisaki, K. Tachibana, Y. Kambayashi, K. Chihara, Y. Seino, K. Fujieda, Evaluation of quality of life in children with GH deficiency and idiopathic short stature using the child behavior checklist. Clin. Pediatr. Endocrinol. 18(1), 15\u201322 (2009). https:\/\/doi.org\/10.1297\/cpe.18.15","journal-title":"Clin. Pediatr. Endocrinol."},{"issue":"11","key":"4269_CR6","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ghir.2018.06.001","volume":"41","author":"\u0130 Akaltun","year":"2018","unstructured":"\u0130. Akaltun, A. \u00c7ay\u0131r, T. Kara, H. Ayayd\u0131n, Is growth hormone deficiency associated with anxiety disorder and depressive symptoms in children and adolescents?: a case-control study. Growth Horm. IGF Res. 41(11), 23\u201327 (2018). https:\/\/doi.org\/10.1016\/j.ghir.2018.06.001","journal-title":"Growth Horm. IGF Res."},{"key":"4269_CR7","doi-asserted-by":"publisher","first-page":"101392","DOI":"10.1016\/j.ghir.2021.101392","volume":"57-58","author":"P Backeljauw","year":"2021","unstructured":"P. Backeljauw, M. Cappa, W. Kiess, L. Law, C. Cookson, C. Sert, J. Whalen, M.T. Dattani, Impact of short stature on quality of life: a systematic literature review. Growth Horm. IGF Res. 57-58, 101392\u2013101392 (2021). https:\/\/doi.org\/10.1016\/j.ghir.2021.101392","journal-title":"Growth Horm. IGF Res."},{"key":"4269_CR8","doi-asserted-by":"publisher","first-page":"e63","DOI":"10.1016\/j.pedn.2019.09.005","volume":"49","author":"R Alsaigh","year":"2019","unstructured":"R. Alsaigh, I. Coyne, Mothers\u2019 experiences of caring for children receiving growth hormone treatment. J. Pediatr. Nurs. 49, e63\u2013e73 (2019). https:\/\/doi.org\/10.1016\/j.pedn.2019.09.005","journal-title":"J. Pediatr. Nurs."},{"issue":"3","key":"4269_CR9","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1515\/jpem-2018-0403","volume":"32","author":"C Drosatou","year":"2019","unstructured":"C. Drosatou, E.A. Vlachopapadopoulou, M. Bullinger, J. Quitmann, N. Silva, G. Salemi, I. Pavlopoulou, S. Michalacos, K. Tsoumakas, Validation of the greek version of the quality of life in short stature youth (QoLISSY) questionnaire. J. Pediatr. Endocrinol. Metab. 32(3), 215\u2013224 (2019). https:\/\/doi.org\/10.1515\/jpem-2018-0403","journal-title":"J. Pediatr. Endocrinol. Metab."},{"issue":"37","key":"4269_CR10","doi-asserted-by":"publisher","first-page":"e22147","DOI":"10.1097\/MD.0000000000022147","volume":"99","author":"KA Majewska","year":"2020","unstructured":"K.A. Majewska, M. Stanis\u0142awska-Kubiak, K. Wieche\u0107, M. Naskr\u0119cka, A. K\u0119dzia, E. Mojs, Maternal anxiety in relation to growth failure and growth hormone treatment in children. Medicine 99(37), e22147 (2020). https:\/\/doi.org\/10.1097\/MD.0000000000022147","journal-title":"Medicine"},{"issue":"1","key":"4269_CR11","doi-asserted-by":"publisher","first-page":"e107","DOI":"10.1002\/cpp.2146","volume":"25","author":"N Silva","year":"2018","unstructured":"N. Silva, M. Bullinger, R. Sommer, A. Rohenkohl, S. Witt, J. Quitmann, Children\u2019s psychosocial functioning and parents\u2019 quality of life in paediatric short stature: the mediating role of caregiving stress. Clin. Psychol. Psychother. 25(1), e107\u2013e118 (2018). https:\/\/doi.org\/10.1002\/cpp.2146","journal-title":"Clin. Psychol. Psychother."},{"issue":"7","key":"4269_CR12","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s00431-014-2480-6","volume":"174","author":"R Sommer","year":"2015","unstructured":"R. Sommer, A. Daubmann, J. Quitmann, U. Ravens-Sieberer, M. Bullinger, Understanding the impact of statural height on health-related quality of life in German adolescents: a population-based analysis. Eur. J. Pediatr. 174(7), 875\u2013882 (2015). https:\/\/doi.org\/10.1007\/s00431-014-2480-6","journal-title":"Eur. J. Pediatr."},{"issue":"5","key":"4269_CR13","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/nrendo.2018.22","volume":"14","author":"MB Ranke","year":"2018","unstructured":"M.B. Ranke, J.M. Wit, Growth hormone-past, present and future. Nat. Rev. Endocrinol. 14(5), 285\u2013300 (2018). https:\/\/doi.org\/10.1038\/nrendo.2018.22","journal-title":"Nat. Rev. Endocrinol."},{"issue":"6","key":"4269_CR14","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1210\/JC.2018-02523","volume":"104","author":"LG Gonzalez Briceno","year":"2019","unstructured":"L.G. Gonzalez Briceno, M. Viaud, J. Beltrand, I. Flechtner, Y. Dassa, D. Samara-Boustani, C. Thalassinos, C. Pauwels, K. Busiah, G. Pinto, D. Jaquet, M. Polak, Improved general and height-specific quality of life in children with short stature after 1 year on growth hormone. J. Clin. Endocrinol. Metab. 104(6), 2103\u20132111 (2019). https:\/\/doi.org\/10.1210\/JC.2018-02523","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"4269_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fped.2019.00164","volume":"7","author":"J Quitmann","year":"2019","unstructured":"J. Quitmann, J. Bloemeke, N. Silva, M. Bullinger, S. Witt, I. Akkurt, D. Dunstheimer, C. Vogel, V. B\u00f6ttcher, U.K. Krahl, M. Bettendorf, E. Sch\u00f6nau, S. Fricke-Otto, A. Keller, K. Mohnike et al. Quality of life of short-statured children born small for gestational age or idiopathic growth hormone deficiency within one year of growth hormone treatment. Front. Pediatr. 7, 1\u201311 (2019). https:\/\/doi.org\/10.3389\/fped.2019.00164","journal-title":"Front. Pediatr."},{"key":"4269_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fendo.2022.795224","volume":"13","author":"R Gomez","year":"2022","unstructured":"R. Gomez, S.F. Ahmed, M. Maghnie, D. Li, T. Tanaka, B.S. Miller, Treatment adherence to injectable treatments in pediatric growth hormone deficiency compared with injectable treatments in other chronic pediatric conditions: a systematic literature review. Front. Endocrinol. 13, 1\u201311 (2022). https:\/\/doi.org\/10.3389\/fendo.2022.795224","journal-title":"Front. Endocrinol."},{"issue":"4","key":"4269_CR17","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1159\/000493211","volume":"90","author":"S Graham","year":"2019","unstructured":"S. Graham, J. Weinman, V. Auyeung, Identifying potentially modifiable factors associated with treatment non-adherence in paediatric growth hormone deficiency: a systematic review. Horm. Res. Paediatr. 90(4), 221\u2013227 (2019). https:\/\/doi.org\/10.1159\/000493211","journal-title":"Horm. Res. Paediatr."},{"issue":"5","key":"4269_CR18","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s40271-017-0237-9","volume":"10","author":"M Brod","year":"2017","unstructured":"M. Brod, L. H\u00f8jbjerre, S.L. Alolga, J.F. Beck, L. Wilkinson, M.H. Rasmussen, Understanding treatment burden for children treated for growth hormone deficiency. Patient 10(5), 653\u2013666 (2017). https:\/\/doi.org\/10.1007\/s40271-017-0237-9","journal-title":"Patient"},{"issue":"4","key":"4269_CR19","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1159\/000350251","volume":"79","author":"BG Fisher","year":"2013","unstructured":"B.G. Fisher, C.L. Acerini, Understanding the growth hormone therapy adherence paradigm: a systematic review. Horm. Res. Paediatr. 79(4), 189\u2013196 (2013). https:\/\/doi.org\/10.1159\/000350251","journal-title":"Horm. Res. Paediatr."},{"key":"4269_CR20","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ghir.2015.12.002","volume":"26","author":"S De Pedro","year":"2016","unstructured":"S. De Pedro, M. Murillo, I. Salinas, M.L. Granada, M. Martinez, M. Puig-Domingo, A. Andreu, J. Bel, Variability in adherence to rhGH treatment: socioeconomic causes and effect on children\u2019s growth. Growth Horm. IGF Res. 26, 32\u201335 (2016). https:\/\/doi.org\/10.1016\/j.ghir.2015.12.002","journal-title":"Growth Horm. IGF Res."},{"issue":"8","key":"4269_CR21","doi-asserted-by":"publisher","first-page":"929","DOI":"10.4158\/EP171786.OR","volume":"23","author":"F Bagnasco","year":"2017","unstructured":"F. Bagnasco, N.D. Iorgi, A. Roveda, A. Gallizia, R. Haupt, M. Maghnie, Prevalence and correlates of adherence in children and adolescents treated with growth hormone: a multicenter Italian study. Endocr. Pract. 23(8), 929\u2013941 (2017). https:\/\/doi.org\/10.4158\/EP171786.OR","journal-title":"Endocr. Pract."},{"issue":"1","key":"4269_CR22","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1515\/jpem-2017-0157","volume":"31","author":"S Mohseni","year":"2018","unstructured":"S. Mohseni, Z. Heydari, M. Qorbani, M. Radfar, Adherence to growth hormone therapy in children and its potential barriers. J. Pediatr. Endocrinol. Metab. 31(1), 13\u201320 (2018). https:\/\/doi.org\/10.1515\/jpem-2017-0157","journal-title":"J. Pediatr. Endocrinol. Metab."},{"key":"4269_CR23","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.2147\/PPA.S177624","volume":"12","author":"S Sultan","year":"2018","unstructured":"S. Sultan, M. El-Hourani, \u00c9. Rondeau, N. Garnier, Categorizing factors of adherence to parenteral treatment in growth hormone deficiencies and hemophilia: what should be the targets for future research? Patient Prefer. Adherence. 12, 2039\u20132063 (2018). https:\/\/doi.org\/10.2147\/PPA.S177624","journal-title":"Patient Prefer. Adherence."},{"key":"4269_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ghir.2018.10.004","volume":"44","author":"A Farfel","year":"2019","unstructured":"A. Farfel, S. Shalitin, N. Morag, J. Meyerovitch, Long-term adherence to growth hormone therapy in a large health maintenance organization cohort. Growth Horm. IGF Res. 44, 1\u20135 (2019). https:\/\/doi.org\/10.1016\/j.ghir.2018.10.004","journal-title":"Growth Horm. IGF Res."},{"issue":"2","key":"4269_CR25","doi-asserted-by":"publisher","first-page":"143","DOI":"10.4158\/EP.14.2.143","volume":"14","author":"RG Rosenfeld","year":"2008","unstructured":"R.G. Rosenfeld, B. Bakker, Compliance and persistence in pediatric and adult patients receiving growth hormone therapy. Endocr. Pract. 14(2), 143\u2013154 (2008). https:\/\/doi.org\/10.4158\/EP.14.2.143","journal-title":"Endocr. Pract."},{"issue":"1","key":"4269_CR26","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1371\/journal.pone.0016223","volume":"6","author":"WS Cutfield","year":"2011","unstructured":"W.S. Cutfield, J.G.B. Derraik, A.J. Gunn, K. Reid, T. Delany, E. Robinson, P.L. Hofman, Non-compliance with growth hormone treatment in children is common and impairs linear growth. PLoS One 6(1), 5\u20137 (2011). https:\/\/doi.org\/10.1371\/journal.pone.0016223","journal-title":"PLoS One"},{"key":"4269_CR27","unstructured":"The European Qo, L.G., Quality of Life in Short Stature Youth the QoLISSY Questionnaire User\u2019s Manual (Pabst Science Publishers, Lengerich, 2013)"},{"issue":"3","key":"4269_CR28","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s40271-019-00405-7","volume":"13","author":"DM Turner-Bowker","year":"2020","unstructured":"D.M. Turner-Bowker, A. Yaworsky, A. Palladino, R.E. Lamoureux, M. Kelly, E. Love, A.M. Pleil, A. Shields, J. Loftus, Development and psychometric evaluation of the life interference questionnaire for growth hormone deficiency (LIQ-GHD) to assess growth hormone injection burden in children and adults. Patient 13(3), 289\u2013306 (2020). https:\/\/doi.org\/10.1007\/s40271-019-00405-7","journal-title":"Patient"},{"issue":"1","key":"4269_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12955-019-1118-9","volume":"17","author":"J Bloemeke","year":"2019","unstructured":"J. Bloemeke, N. Silva, M. Bullinger, S. Witt, H.G. D\u00f6rr, J. Quitmann, Psychometric properties of the quality of life in short statured youth (QoLISSY) questionnaire within the course of growth hormone treatment. Health Qual. Life Outcomes. 17(1), 1\u201315 (2019). https:\/\/doi.org\/10.1186\/s12955-019-1118-9","journal-title":"Health Qual. Life Outcomes."},{"issue":"2","key":"4269_CR30","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1080\/03007995.2023.2290623","volume":"40","author":"J Loftus","year":"2024","unstructured":"J. Loftus, J. Quitmann, S.R. Valluri, Health-related quality of life in pre-pubertal children with pediatric growth hormone deficiency: 12-month results from a phase 3 clinical trial of once-weekly somatrogon versus once-daily somatropin. Curr. Med. Res. Opin. 40(2), 175\u2013184 (2024). https:\/\/doi.org\/10.1080\/03007995.2023.2290623","journal-title":"Curr. Med. Res. Opin."},{"issue":"4","key":"4269_CR31","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1097\/PEP.0000000000000638","volume":"31","author":"CA Hall","year":"2019","unstructured":"C.A. Hall, C. Donza, S. McGinn, A. Rimmer, S. Skomial, E. Todd, F. Vaccaro, Health-related quality of life in children with chronic illness compared to parents: a systematic review. Pediatr. Phys. Ther. 31(4), 315\u2013322 (2019). https:\/\/doi.org\/10.1097\/PEP.0000000000000638","journal-title":"Pediatr. Phys. Ther."},{"issue":"12","key":"4269_CR32","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1007\/s40618-023-02106-3","volume":"46","author":"M Maghnie","year":"2023","unstructured":"M. Maghnie, M. Orso, B. Polistena, M. Cappa, G. Pozzobon, D. d\u2019Angela, G. Patti, F. Spandonaro, S. Granato, R. Di Virgilio, D. La Torre, M. Salerno, Quality of life in children and adolescents with growth hormone deficiency and their caregivers: an Italian survey. J. Endocrinol. Invest. 46(12), 2513\u20132523 (2023). https:\/\/doi.org\/10.1007\/s40618-023-02106-3","journal-title":"J. Endocrinol. Invest."},{"issue":"4","key":"4269_CR33","doi-asserted-by":"publisher","first-page":"e220464","DOI":"10.1530\/EC-22-0464","volume":"12","author":"R Coutant","year":"2023","unstructured":"R. Coutant, M. Tauber, B. Demaret, R. Henocque, Y. Brault, F. Montestruc, O. Chassany, M. Polak, Treatment burden, adherence, and quality of life in children with daily GH treatment in France. Endocr. Connect. 12(4), e220464 (2023). https:\/\/doi.org\/10.1530\/EC-22-0464","journal-title":"Endocr. Connect."},{"issue":"6","key":"4269_CR34","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.eprac.2022.02.013","volume":"28","author":"J Loftus","year":"2022","unstructured":"J. Loftus, B.S. Miller, C.S. Parzynski, J. Alvir, Y. Chen, P. Jhingran, A. Gupta, M. DeKoven, V. Divino, J. Tse, J. He, M. Wajnrajch, Association of daily growth hormone injection adherence and height among children with growth hormone deficiency. Endocr. Pract. 28(6), 565\u2013571 (2022). https:\/\/doi.org\/10.1016\/j.eprac.2022.02.013","journal-title":"Endocr. Pract."},{"issue":"4","key":"4269_CR35","doi-asserted-by":"publisher","first-page":"329","DOI":"10.4274\/jcrpe.galenos.2019.2019.0088","volume":"11","author":"JM Wit","year":"2019","unstructured":"J.M. Wit, Achieving optimal short- and long-term responses to paediatric growth hormone therapy. J. Clin. Res. Pediatr. Endocrinol. 11(4), 329\u2013340 (2019)","journal-title":"J. Clin. Res. Pediatr. Endocrinol."},{"issue":"10","key":"4269_CR36","doi-asserted-by":"publisher","first-page":"bvac117","DOI":"10.1210\/jendso\/bvac117","volume":"6","author":"AK Maniatis","year":"2022","unstructured":"A.K. Maniatis, M. Carakushansky, S. Galcheva, G. Prakasam, L.A. Fox, A. Dankovcikova, J. Loftus, A.A. Palladino, M. De Los Angeles Resa, C. Turich Taylor, M.T. Dattani, J. Lebl, Treatment burden of weekly somatrogon vs daily somatropin in children with growth hormone deficiency: a randomized study. J. Endocr. Soc. 6(10), bvac117 (2022). https:\/\/doi.org\/10.1210\/jendso\/bvac117","journal-title":"J. Endocr. Soc."},{"issue":"10","key":"4269_CR37","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1111\/ped.14760","volume":"63","author":"T Tanaka","year":"2021","unstructured":"T. Tanaka, T. Sato, A. Yuasa, T. Akiyama, A. Tawseef, Patient preferences for growth hormone treatment in Japanese children. Pediatr. Int. 63(10), 1185\u20131191 (2021). https:\/\/doi.org\/10.1111\/ped.14760","journal-title":"Pediatr. Int."},{"key":"4269_CR38","doi-asserted-by":"publisher","first-page":"781","DOI":"10.2147\/PPA.S239196","volume":"14","author":"M McNamara","year":"2020","unstructured":"M. McNamara, D.M. Turner-Bowker, H. Westhead, A. Yaworsky, A. Palladino, H. Gross, A. Pleil, J. Loftus, Factors driving patient preferences for growth hormone deficiency (Ghd) injection regimen and injection device features: a discrete choice experiment. Patient Prefer. Adherence. 14, 781\u2013793 (2020). https:\/\/doi.org\/10.2147\/PPA.S239196","journal-title":"Patient Prefer. Adherence."},{"issue":"2","key":"4269_CR39","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1136\/adc.2006.114249","volume":"93","author":"RR Kapoor","year":"2008","unstructured":"R.R. Kapoor, S.A. Burke, S.E. Sparrow, I.A. Hughes, D.B. Dunger, K.K. Ong, C.L. Acerini, Monitoring of concordance in growth hormone therapy. Arch. Dis. Child. 93(2), 147\u2013148 (2008). https:\/\/doi.org\/10.1136\/adc.2006.114249","journal-title":"Arch. Dis. Child."},{"issue":"6","key":"4269_CR40","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.endinu.2018.02.003","volume":"65","author":"MA Arrabal Vela","year":"2018","unstructured":"M.A. Arrabal Vela, C.P. Garc\u00eda Gij\u00f3n, M. Pascual Martin, I. Benet Gim\u00e9nez, V. \u00c1reas del \u00c1guila, J.R. Mu\u00f1oz-Rodr\u00edguez, E. Palomo Atance, Adherence to somatotropin treatment administered with an electronic device. Endocrinol. Diabetes Nutr. 65(6), 314\u2013318 (2018). https:\/\/doi.org\/10.1016\/j.endinu.2018.02.003","journal-title":"Endocrinol. Diabetes Nutr."},{"issue":"1","key":"4269_CR41","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13052-018-0548-z","volume":"44","author":"MC Maggio","year":"2018","unstructured":"M.C. Maggio, B. Vergara, P. Porcelli, G. Corsello, Improvement of treatment adherence with growth hormone by easypod \u2122 device: experience of an Italian centre. Ital. J. Pediatr. 44(1), 113 (2018)","journal-title":"Ital. J. Pediatr."},{"issue":"4","key":"4269_CR42","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1159\/000437305","volume":"84","author":"N Lass","year":"2015","unstructured":"N. Lass, T. Reinehr, Low treatment adherence in pubertal children treated with thyroxin or growth hormone. Horm. Res. Paediatr. 84(4), 240\u2013247 (2015). https:\/\/doi.org\/10.1159\/000437305","journal-title":"Horm. Res. Paediatr."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04269-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-025-04269-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-025-04269-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T18:38:36Z","timestamp":1757183916000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-025-04269-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,9]]},"references-count":42,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["4269"],"URL":"https:\/\/doi.org\/10.1007\/s12020-025-04269-w","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,9]]},"assertion":[{"value":"21 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"A. Christoforidis has received consulting fees, honoraria and travel support from Sandoz, Pfizer, Novo Nordisk and Eli Lilly. F. E. Karachaliou has served as consultant, advisor, and has received honoraria and travel support from Pfizer, Novo Nordisk, Sandoz and Serono. A. Galli-Tsinopoulou has served as consultant, advisor, and has received honoraria and travel support from Astra Zeneca, Novo Nordisk, Biomarin, Genesis and Pfizer. D. Chrysis has received grants and travel support from Pfizer, Novo Nordisk, Merck and Pfizer. C. Kanaka-Gantenbein has served as consultant, advisor, and has received grants, honoraria and travel support from Novo Nordisk, BioMarin, Genesis, Sandoz, Eli Lilly and Pfizer. Also, C. Kanaka-Gantenbein is the vice president of the Hellenic Society for Pediatric and Adolescent Endocrinology. E. A. Vlachopapadopoulou has served as consultant, advisor, and has received grants, honoraria and travel support from Novo Nordisk, Amgen, Sandoz, Pfizer, BioMarin and Ascendis. I. Skiadas, O. Zisimopoulou, E. Baxevanidi, D. Tsilakis, and A. Poimenidou are employees of Pfizer and may hold stock or stock options.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and the Guidelines for Good Pharmacoepidemiology Practices (GPP) issued by the International Society for Pharmacoepidemiology (ISPE). The study protocol, protocol amendments, and informed consent forms were approved by the institutional review board (IRB)\/independent ethics committee (IEC) of the participating centres.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Signed informed consent was obtained from patients\u2019 guardians as well as patient\u2019s assent (written or verbal depending on patient \u2018s age) as applicable before any study procedures commenced.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}